Neuroblastoma staging
Neuroblastoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Neuroblastoma staging On the Web |
American Roentgen Ray Society Images of Neuroblastoma staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2] Zahir Ali Shaikh, MD[3]
Overview
According to the conventional International Neuroblastoma Staging System (INSS), there are 6 stages of neuroblastoma based on the tumor size, lymph node involvement, and presence of metastasis. However, according to a newly proposed International Neuroblastoma Risk Group Staging System (INRGSS), there are four stages of neuroblastoma based on the extent of dissemination and image findings. Neuroblastoma patients are risk stratified according to the Children Oncology Group (COG) risk stratification system into a low risk group, an intermediate risk group, and a high risk group based on the tumor INSS stage, the patient's age, tumor grade, and the amplification of MYCN gene.
Neuroblastoma Staging
International Neuroblastoma Staging System (INSS)
- According to the conventional International Neuroblastoma Staging System (INSS), there are 6 stages of neuroblastoma based on the tumor size, lymph node involvement, and presence of metastasis.[1][2][3][4][5]
Stage | Description |
Stage 1 |
|
Stage 2A |
|
Stage 2B |
|
Stage 3 |
|
Stage 4 |
|
Stage 4S |
|
International Neuroblastoma Risk Group Staging System (INRGSS)
According to a newly proposed International Neuroblastoma Risk Group Staging System (INRGSS), there are four stages of neuroblastoma based on the extent of dissemination and image findings.[2][6][7][8]
Stage | Description |
Stage L1 |
|
Stage L2 |
|
Stage M | |
Stage MS |
|
Risk Stratification
Children's Oncology Group Risk Stratification
- Children Oncology Group (COG) risk stratification system determines the protocol of management used for neuroblastoma patients.[9]
- Neuroblastoma patients are risk stratified into a low risk group, intermediate risk groups, and a high risk group based on the INSS stage, the patient's age, histological grade, and the amplification of MYCN gene.[1][2][10]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Low risk neuroblastoma patients (group 1) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Intermediate risk neuroblastoma patients (group 2) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Intermediate risk neuroblastoma patients (group 3) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intermediate risk neuroblastoma patients (group 4) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
High risk neuroblastoma patients (group 5) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ 1.0 1.1 Davidoff AM (2012). "Neuroblastoma". Semin Pediatr Surg. 21 (1): 2–14. doi:10.1053/j.sempedsurg.2011.10.009. PMC 3261589. PMID 22248965.
- ↑ 2.0 2.1 2.2 Colon NC, Chung DH (2011). "Neuroblastoma". Adv Pediatr. 58 (1): 297–311. doi:10.1016/j.yapd.2011.03.011. PMC 3668791. PMID 21736987.
- ↑ H. Shimada, S. Umehara, Y. Monobe, Y. Hachitanda, A. Nakagawa, S. Goto, R. B. Gerbing, D. O. Stram, J. N. Lukens & K. K. Matthay (2001). "International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group". Cancer. 92 (9): 2451–2461. PMID 11745303. Unknown parameter
|month=
ignored (help) - ↑ D. de Sa (2000). "Neuroblastoma classification". Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society. 3 (5): 506–507. PMID 10890940. Unknown parameter
|month=
ignored (help) - ↑ S. Goto, S. Umehara, R. B. Gerbing, D. O. Stram, G. M. Brodeur, R. C. Seeger, J. N. Lukens, K. K. Matthay & H. Shimada (2001). "Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group". Cancer. 92 (10): 2699–2708. PMID 11745206. Unknown parameter
|month=
ignored (help) - ↑ Susan L. Cohn, Andrew D. J. Pearson, Wendy B. London, Tom Monclair, Peter F. Ambros, Garrett M. Brodeur, Andreas Faldum, Barbara Hero, Tomoko Iehara, David Machin, Veronique Mosseri, Thorsten Simon, Alberto Garaventa, Victoria Castel & Katherine K. Matthay (2009). "The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27 (2): 289–297. doi:10.1200/JCO.2008.16.6785. PMID 19047291. Unknown parameter
|month=
ignored (help) - ↑ Tom Monclair, Garrett M. Brodeur, Peter F. Ambros, Herve J. Brisse, Giovanni Cecchetto, Keith Holmes, Michio Kaneko, Wendy B. London, Katherine K. Matthay, Jed G. Nuchtern, Dietrich von Schweinitz, Thorsten Simon, Susan L. Cohn & Andrew D. J. Pearson (2009). "The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27 (2): 298–303. doi:10.1200/JCO.2008.16.6876. PMID 19047290. Unknown parameter
|month=
ignored (help) - ↑ Sidharth Mahapatra & Kishore B.. Challagundla (2018). "Cancer, Neuroblastoma". PMID 28846355. Unknown parameter
|month=
ignored (help) - ↑ Neuroblastoma treatment–for health professionals. National Cancer Institute (2015) http://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq#section/_1 Accessed on October, 8 2015
- ↑ Nadja C. Colon & Dai H. Chung (2011). "Neuroblastoma". Advances in pediatrics. 58 (1): 297–311. doi:10.1016/j.yapd.2011.03.011. PMID 21736987.